Business Description
Evelo Biosciences Inc
NAICS : 325411
SIC : 2833
ISIN : US2997342025
Description
Evelo Biosciences Inc is a clinical-stage biotechnology company focused on discovering and developing a new class of oral medicines that act on immune cells in the small intestine with systemic effects. The company is developing EDP1815 as a treatment in psoriasis and atopic dermatitis and EDP2939 in psoriasis.
Financial Strength
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 33.86 | |||||
9-Day RSI | 41.19 | |||||
14-Day RSI | 43.86 | |||||
6-1 Month Momentum % | -80 | |||||
12-1 Month Momentum % | -80 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History |
|---|
GF Value Rank
| Name | Current | Vs Industry | Vs History |
|---|
GF Valueâ„¢
Evelo Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Evelo Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 139 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | In 54 days | ||
| Annual report for 2025 | 2026-07-01 | In 4 days | ||
| First quarter earnings results for 2026 | 2026-07-01 | In 4 days | ||
| General meeting for 2025 | 2026-06-30 | In 3 days | ||
| 0.05:1 Stock Split | 2023-06-30 | 3.53 (-7.45%) |
Show
Entries
Guru Commentaries on OTCPK:EVLO
No articles.
Press Release
Articles on Evelo Biosciences Inc
No articles.